Physician profile
Michael W Goodman
NPI 1639171481
$7,218.20
in general payments reported to CMS, 2019-2025
29 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $549 · 2021: $1,040 · 2022: $1,036 · 2023: $1,263 · 2024: $1,196 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,591 · Education: $41.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,591.05 |
| Education | $41.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,879.82 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,421.15 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,074.56 | 2019-2025 | Xifaxan |
| Pfizer INC. | $940.65 | 2019-2025 | |
| Janssen Biotech, INC. | $214.85 | 2020-2025 | Tremfya, Stelara, Simponi |
| Celltrion USA INC. | $177.96 | 2024-2025 | Vegzelma, Zymfentra |
| Gilead Sciences, INC. | $137.81 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $133.92 | 2020-2023 | Linzess |
| Evoke Pharma, INC. | $109.51 | 2020-2025 | Gimoti |
| Braintree Laboratories, INC. | $107.77 | 2019-2023 | Suflave |
| Merck Sharp & Dohme LLC | $102.15 | 2019-2022 | |
| Amgen INC. | $96.59 | 2021-2023 | Amjevita, Avsola |
| Phathom Pharmaceuticals, INC. | $91.87 | 2023-2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $84.79 | 2019-2021 | |
| Qol Medical, LLC | $75.92 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $74.44 | 2021-2022 | |
| Madrigal Pharmaceuticals | $71.93 | 2024-2025 | Resmetirom, Rezdiffra |
| Intra-Sana Laboratories | $56.71 | 2022-2023 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Boston Scientific Corporation | $55.89 | 2024-2025 | Axios, Compliance Endokit, Overstitch Nxt Endoscopic Suturing System |
| Endo Pharmaceuticals INC. | $52.63 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $48.11 | 2024 | |
| Organon LLC | $34.70 | 2023 | Hadlima, Renflexis |
| Daiichi Sankyo INC. | $30.25 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $29.65 | 2024 | Dupixent |
| Ferring Pharmaceuticals INC. | $29.37 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $25.47 | 2024 | Iqirvo |
| Romark Laboratories, Lc | $22.93 | 2020 | |
| Lilly USA, LLC | $21.97 | 2024 | Omvoh |
| Endogastric Solutions, INC | $14.83 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.